In collaboration with teams from the AP-HP, the University of Paris and the Sorbonne University, we have carried out work on the effect of immune checkpoint inhibitors (anti-PD1 and anti-CTLA4) on cellular immunity against SARS-CoV-2. This work suggests that these treatments are not deleterious during infection with COVID-19 and, on the contrary, seem to improve the antiviral cellular immune response.
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection, Science Advances, Aug. 18, 2021
To read the article: here
To read the news: here